Learn More
R&D Systems™ Recombinant Human Endorepellin Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 2364ER050
Description
Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt-1 (Catalog # 321-FL ) is coated at 5μg/mL (100μL/well), the concentration of Recombinant Human Endorepellin/Perlecan that produces 50% of the optimal binding response is approximately 0.75-6μg/mL.
The Recombinant Human Endorepellin Protein is derived from NS0. The Recombinant Human Endorepellin Protein has been validated for the following applications: Bioactivity.Specifications
Lyophilized from a 0.2μm filtered solution in PBS with Trehalose. | |
76.7 kDa | |
50μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
Unconjugated | |
95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
3339 | |
Endorepellin/Perlecan | |
Mouse myeloma cell line,NS0-derived human Endorepellin/Perlecan protein Arg3684-Ser4391 (Ser4004Thr),with a C-terminal 10-His tag | |
basement membrane-specific heparan sulfate proteoglycan core protein, endorepellin (domain V region), heparan sulfate proteoglycan 2, HSPG, perlecan, perlecan proteoglycan, PLCSchwartz-Jampel syndrome 1 (chondrodystrophic myotonia), PRCAN, SJA, SJS, SJS1 | |
Recombinant |
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.